Thn102 dosage a (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03624920 (ClinicalTrials.gov) | July 12, 2018 | 10/7/2018 | Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness | Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness | Parkinson Disease | Drug: THN102 Dosage A;Drug: THN102 Dosage B;Drug: THN102 Dosage C | Theranexus | NULL | Completed | 18 Years | 80 Years | All | 77 | Phase 2 | United States;Czechia;France;Germany;Hungary |